BJMO - volume 9, issue 6, november 2015
K. Papadimitriou MD, M. Rasschaert MD, J. Van den Brande , M. Peeters MD, PhD
A large body of trials, including large adjuvant phase III trials up to early phase trials was presented during the 2015 European Cancer Congress (ECC). Immunotherapy, was once more in the center of the scientific interest for different types of cancer and settings. This report will focus on some of the key studies presented during the meeting, referring to gastrointestinal cancer.
(BELG J MED ONCOL 2015;9:217–21)
Read moreBJMO - volume 9, issue 4, august 2015
K. Papadimitriou MD, M. Rasschaert MD, J. Van den Brande , M. Peeters MD, PhD
The 2015 ASCO Annual Meeting represents the 50th anniversary celebration from ASCO’s foundation. This is the beginning of the second half of our first 100 years. We’re going to think about what cancer and cancer care delivery will look like 10, 20, or 30 years from now,” said the 2014– 2015 ASCO President, Peter Paul Yu. The chosen theme of this year’s meeting is “Illumination and Innovation: Transforming Data into Learning” as reflected in Dr. Yu’s question “How do we harness our vastly increasing knowledge base and deliver the fruits of that labor to our patients?”
In gastrointestinal oncology results, updates and sub analyses of phase III trials were presented but also many negative trials. Data from early phase trials in the fields of immunology, incorporating new promising treatments like anti-PD-1, potential related markers and HER2 receptor blockage were also of interest. Furthermore, debates with a focus on financial aspects of treatment approaches, including the innovative, but yet very expensive immune modulation therapies, and comparisons of standard “targeted” approaches were discussed.
(BELG J MED ONCOL 2015;9:143–8)
Read moreBJMO - volume 9, issue 1, february 2015
Z. El Ali MD, PhD, D. Van Brummelen MD, P. Wolter MD, S. Rottey MD, PhD, S. Altintas MD, PhD, D. Schallier MD, PhD, P. Debruyne MD, PhD, C. Gennigens MD, F. Van Aelst MD, S. Sideris MD, T. Gil MD, N. Sirtaine MD, L. D’Hondt MD, PhD, D. Luyten MD, C. Focan MD, PhD, G. Matus MD, M. Rasschaert MD, G. Pelgrims MD, the BSMO Renal Cancer Task Force Group
Almost 30% of patients with renal cell cancer present initially with advanced stage IV disease. In the past decade, the management of the metastatic renal cell cancer has been revolutionised by the knowledge of its molecular biology and development of targets against vascular endothelial growth factor and mammalian target of rapamycin pathways. In this paper we present recommendations based on a thorough review of available guidelines and data from the phase III randomised controlled trials that evaluated new agents in patients with advanced metastatic renal cancer.
(BELG J MED ONCOL 2015;9(1):16–24)
Top
